IP Library Granted Patent US 12,491,246
Granted Patent B2
US 12,491,246 · App. 17/312,419 · Granted Dec 9, 2025

Combination therapy of arms and natural killer cells

Inventors: Luca Rastelli (Madison, CT); Anna Bunin (Hamden, CT)
Assignee: BIOHAVEN THERAPEUTICS LTD.
A61K40/15A61K38/08A61K38/12A61K39/395A61K40/4212A61K47/545A61K47/60A61K47/62A61K47/64A61P35/00A61K2239/31A61K2239/38A61K2239/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,491,246
App. No.
17/312,419
Granted
Dec 9, 2025
Kind
B2
Abstract

Among other things, the present disclosure provides technologies comprising immune cells and antibody-recruiting molecules. In some embodiments, immune cells are memory-like natural killer cells. In some embodiments, provided technologies are particularly useful for treating a condition, disorder or disease like cancer. In some embodiments, provided technologies provide high efficacy. In some embodiments, provided technologies provide less or less severe side effects associated with natural killer cell therapy.

Claims (22)

1 . A composition comprising:

a plurality of natural killer cells; and

an antibody-recruiting molecule (ARM), wherein:

the ARM is a compound of the formula

 or a pharmaceutically acceptable salt thereof.

2 . The composition of claim 1 , wherein the natural killer cells are memory-like natural killer cells or cytokine-induced memory-like natural killer cells induced by IL-12, IL-15 and IL-18.

3 . An ARM of the formula

or a pharmaceutically acceptable salt thereof.

4 . A pharmaceutical composition comprising a compound or salt of claim 3 , and a pharmaceutically acceptable excipient.

5 . A method for inducing cancer cell death, inhibiting cancer cell growth, and/or reducing the number of cancer cells in a human subject, comprising administering to the human subject:

the antibody-recruiting molecule (ARM), or pharmaceutically acceptable thereof of claim 3 , and

a plurality of natural killer cells;

so that the system is exposed to both the ARM and the plurality of natural killer cells and the number of cancer cells in the system is reduced compared to absence of both the natural killer cells and the antibody recruiting molecule.

6 . A method for treating cancer, comprising administering to a subject suffering therefrom:

a plurality of natural killer cells;

a therapeutically effective amount of the antibody-recruiting molecule (ARM) or pharmaceutically acceptable salt thereof of claim 3 .

7 . The method of claim 6 , wherein the cancer is multiple myeloma.

8 . The method of claim 5 , wherein the method includes administering natural killer cells and the natural killer cells are memory-like natural killer cells.

9 . The method of claim 5 , wherein the method includes administering natural killer cells and the natural killer cells are cytokine-induced memory-like natural killer cells induced by IL-12, IL-15 and IL-18.

10 . The method of claim 8 , wherein the natural killer cells and the ARM are administered concurrently, optionally in one composition.

11 . The method of claim 8 , wherein the natural killer cells are administered prior to or subsequently to the ARM.

12 . The method of claim 8 , wherein the ARM is administered with an antibody or a fragment thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 27, 2025
From: SIXTH STREET SPECIALTY LENDING, INC.
To: BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.; BIOHAVEN THERAPEUTICS LTD.; BIOHAVEN PHARMACEUTICAL IRELAND DESIGNATED ACTIVITY COMPANY
Reel/Frame 071083/0330 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2022
From: KLEO PHARMACEUTICALS, INC.
To: BIOHAVEN THERAPEUTICS LTD.
Reel/Frame 060177/0428 →
PATENT SECURITY AGREEMENT Recorded Dec 2, 2021
From: KLEO PHARMACEUTICALS INC.
To: SIXTH STREET SPECIALTY LENDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 058299/0321 →
Continuity (2)
Provisional Application 62783036 · Dec 20, 2018
Related Publication 20220040231A1 · Feb 10, 2022
References Cited (40)
US 20040253247A1 · Dennis et al. · 2004 [cited by applicant]
US 20060292156A1 · Campbell · 2006 [cited by applicant]
US 20080029274A1 · Rytlewski et al. · 2008 [cited by applicant]
US 20160082112A1 · Spiegel et al. · 2016 [cited by applicant]
US 20160346403A1 · Prudent · 2016 [cited by applicant]
US 20160356095A1 · Perez et al. · 2016 [cited by applicant]
US 20180155332A1 · Spiegel et al. · 2018 [cited by applicant]
US 20180230184A1 · Minami · 2018 [cited by applicant]
US 20180311300A1 · Beswick et al. · 2018 [cited by applicant]
US 20230028880A1 · Rastelli et al. · 2023 [cited by applicant]
EP 1251598A1 · 2002 [cited by applicant]
EP 2188487B1 · 2015 [cited by applicant]
WO 2009139863A2 · 2009 [cited by applicant]
WO 2015044208A2 · 2015 [cited by applicant]
WO 2018089476A1 · 2018 [cited by applicant]
WO 2018197509A1 · 2018 [cited by applicant]
WO 2018222987A1 · 2018 [cited by applicant]
WO 2019002842A1 · 2019 [cited by applicant]
WO 2019023501A1 · 2019 [cited by applicant]
Achilli et al., “Antibody Recruiting Molecules (ARMS): Synthetic Immunotherapeutics to Fight Cancer,” RSC Chemical Biology, (2021), vol. 2, (No. 3), 713-724. [cited by applicant]
Bhat et al., “Serial Killing of Tumor Cells by Human Natural Killer Cells—Enhancement by Therapeutic Antibodies,” Plos One, (2007), vol. 2, (No. 3), 1-7. [cited by applicant]
Bunin et al., “A Novel Class of Bifunctional Immunotherapeutic that Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo Efficacy in Three Di… [cited by applicant]
Burga et al., “Improving Efficacy of Cancer Immunotherapy by Genetic Modification of Natural Killer Cells,” International Society for Cellular Therapy, (2016), vol. 18, (No. 11), 1410-1421. [cited by applicant]
Corson et al., “Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One,” ACS Chemical Biology, (2008), vol. 3, (No. 11), 1-25. [cited by applicant]
Extended European Search Report for Application No. 19900293.2-1112 /3898701 PCT/US2019/068086, dated Sep. 28, 2022, 9 pages. [cited by applicant]
Mcenaney et al., “Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease,” ACS Chemical Biology, (2012), vol. 7, (No. 7), 1139-1151. [cited by applicant]
Parihar et al., “IL-12 Enhances the Natural Killer Cell Cytokine Response to Ab-Coated Tumor Cells,” Journal of Clinical Investigation, (2002), vol. 110, (No. 7), 983-992. [cited by applicant]
Rullo et al., “Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor,” Angewandte Chemie, Wiley-VCH Verlag Gmbh & Co., (2016), vol. 128, (No. 11), … [cited by applicant]
International Search Report dated Mar. 30, 2020 issued for the corresponding application PCT/US2020/068086 (2 pages). [cited by applicant]
Written Opinion dated Mar. 30, 2020 issued for the corresponding application PCT/US2020/068086 (8 pages). [cited by applicant]
Choe, et al., “Fc-Binding Ligands of Immunoglobulin G: An Overview of High Affinity Proteins and Peptides” Materials 2016 vol. 9, No. 994, (pp. 1-17). [cited by applicant]
Perdomo, et al., “Neutralization of HIV-1 by redirection of natural antibodies” Proc Natl Acad Sci USA, Aug. 21, 2008, vol. 105, No. 34 (pp. 12515-12520). [cited by applicant]
Sasaki, et al., “A peptide inhibitor of antibody-dependent cell-mediated cytotoxicity against EGFR/folate receptor-α double positive cells” Medchemcomm, Feb. 26, 2018, vol. 9, No. 5 (pp. 783-788). [cited by applicant]
Extended European Search Report for EP Application No. 20834827.6; Dated—Sep. 12, 2023; 9 pages. [cited by applicant]
International Preliminary Report dated Dec. 28, 2021 issued for International Application No. PCT/US2020/39466 (10 pages). [cited by applicant]
International Search Report; International Application No. PCT/US2020/39466; International Filing Date—Jun. 24, 2020; Date of Mailing—Jan. 5, 2021; 6 pages. [cited by applicant]
Jakab et al., “Synthesis and Antibody Recognition of Cyclic Epitope Peptides, Together with Their Dimer and Conjugated Derivatives Based on Residues 9-22 of Herpes Simplex Virus Type 1 Glycoprotein D,” Bioconjugate Chem… [cited by applicant]
Written Opinion; International Application No. PCT/US2020/39466; International Filing Date—Jun. 24, 2020; Date of Mailing—Jan. 5, 2021; 9 pages. [cited by applicant]
Kang et al., “Developing an antibody-binding protein cage as a molecular recognition drug modular nanoplatform” Biomaterials 33 5423-5430 (2012). [cited by applicant]
Yoon et al., “Understanding of molecular mechanisms in natural killer cell therapy” Experimental& Molecular Medicine, 2015, vol. 47, e141, 12 pages. [cited by applicant]